Shenyang Dongxing Pharmaceutical Technology Co., Ltd. Report issue

For profit Phase 1
Founded: Shenyang China (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2018
NCT03794843
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Shenyang Dongxing Pharmaceutical Technology Co., Ltd.

Active Ingredients

Drugs in Phase 1 Trials (1)

nimodipine (nimotop) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebrovascular Disorders (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1